Author(s)

George Badavanis¹, Efstathia Pasmatzi², Alexandra Monastirli^1,2, Dionysios Tsambaos^1,2

¹Center for Dermatologic Diseases, Limassol, Cyprus.
²Department of Dermatology, University of Patras, Patras, Greece.

Pyogenic granuloma (PG) is a benign vascular proliferation of the skin and mucosae, that has been treated with different regimens with variable success and recurrence rates; however, the management of PG still remains a challenging issue, particularly in children and in adult cases with lesions localized at sites difficult to access. Imiquimod, a member of the imidazoquinoline family of immune response modifiers, is a topically applicable TLR-7/8 agonist that reveals potent antiviral, antitumor, immunoregulatory and antiangiogenic properties. In the present paper we report the case of a 9-year old boy with suborbital pyogenic granuloma, successfully treated with topical daily application of imiquimod 5% cream without occlusion. 8 weeks after onset of topical imiquimod treatment a complete resolution of the lesion without any scarring was observed. No systemic side effects were seen and the patient remained well throughout the course of therapy. He is presently completing a 15-month follow-up and has revealed no relapse. The findings of the present study suggest that topical imiquimod is a safe, effective and well-tolerated treatment for PG in children, even at difficult to treat areas like the suborbital region.

Pyogenic Granuloma, Imiquimod, Children, Angiogenesis

Badavanis, G. , Pasmatzi, E. , Monastirli, A. and Tsambaos, D. (2018) Successful Treatment of Suborbital Pyogenic Granuloma with Topical Imiquimod. Case Reports in Clinical Medicine, 7, 1-6. doi: 10.4236/crcm.2018.71001.